||Recombinant Human Prostacyclin was expressed in yeast.
||Prostacyclin is produced in endothelial cells from prostaglandin H2 (PGH2) by the action of the enzyme prostacyclin synthase. Although prostacyclin is considered an independent mediator, it is called PGI2 in eicosanoid nomenclature, and is a member of the prostanoids.The series-3 prostaglandin PGH3 also follows the prostacyclin synthase pathway, yielding another prostacyclin, PGI3. The unqualified term "prostacyclin" usually refers to PGI2. PGI2 is derived from the ω-6 arachidonic acid. PGI3 is derived from the ω-3 EPA. Prostacyclin (PGI2) chiefly prevents formation of the platelet plug involved in primary hemostasis (a part of blood clot formation). It does this by inhibiting platelet activation. It is also an effective vasodilator. Prostacyclin"s interactions in contrast to thromboxane (TXA2), another eicosanoid, strongly suggest a mechanism of cardiovascular homeostasis between the two hormones in relation to vascular damage.
||Lyophilized from sterile 20mM PB,240mM NaCl,PH6.0.
||< 1.0 eu per μg of the protein as determined by the LAL method.
||>95 % as determined by SDS-PAGE
||Western blotting, ELISA
||Store it under sterile conditions at -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.Samples are stable for up to twelve months from date of receipt at -80℃.